When To End A REMS? Soliris Review Stirs Debate On How To Scale Back
Executive Summary
Risk management program for Alexion’s orphan drug eculizumab appears to be succeeding, but what does FDA need to see to make it less burdensome?
You may also be interested in...
If It Ain’t Broke…: FDA Committee Supports Retaining Soliris REMS
FDA’s annual REMS reviews haven’t been the most dramatic advisory committees in recent years. The latest review is the first to involve a major commercial product – Alexion’s Soliris – but also looked at a program that appears successful and non-controversial.
NICE's Nod To Soliris Tainted By Request For R&D Cost Data
The U.K.s NICE is on the verge of recommending Alexion's Soliris for aHUS despite an astronomic price; but its request for R&D cost data will alarm the drug industry.
FDA Panelist Questions Marketing Benefits From Soliris REMS
Cleveland Clinic hematologist suggests eculizumab risk management plan provides Alexion with an opportunity for direct-to-consumer marketing.